Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2019—Quest Diagnostics announced the availability of its test panel to guide therapy with HIV pre-exposure prophylaxis, or PrEP. PrEP is the use of antiretroviral drugs to help prevent HIV infection in high-risk individuals who are not infected.
September 2019—Thermo Fisher Scientific previewed its Sensititre Aris HiQ AST System at the 71st annual AACC meeting. The benchtop automated reading and incubation system for antimicrobial susceptibility testing uses broth microdilution to provide minimum inhibitory concentration results.
September 2019—The U.S. Food and Drug Administration permitted marketing of the Synovasure Lateral Flow Test Kit (CD Diagnostics) as an aid for the detection of periprosthetic joint infection in the synovial fluid of patients being evaluated for revision surgery. The test kit detects human alpha defensins in the synovial fluid of patients with a total joint replacement in approximately 10 minutes. The test is not intended to identify a specific type of infection.
September 2019—Mesa Biotech launched its respiratory syncytial virus test, the company’s second point-of-care test on its polymerase chain reaction testing platform, the Accula System, at the AACC annual scientific meeting. The Accula Flu A/Flu B test received FDA clearance in 2018. Both tests are indicated for use with nasal swab collection.
September 2019—Randox launched at the AACC annual meeting the Randox Stroke Biochip, a highly sensitive blood test that complements CT scanning technology to facilitate accurate classification of stroke patients. The test differentiates between ischemic and hemorrhagic stroke, directs the appropriate patient care pathway, and enables rapid thrombolytic therapy.
September 2019—Veravas launched three biotin interference products, VeraTest Biotin, VeraPrep Biotin, and VeraBind Biotin, for research use only.
September 2019—Caris Life Sciences has entered into a strategic collaboration with Debiopharm for the development of a companion diagnostic test using Caris’ whole transcriptome sequencing assay for mRNA analysis called MI Transcriptome. The assay, which was granted breakthrough device designation by the FDA in May, detects rare fibroblast growth factor receptor (FGFR1, FGFR2, and FGFR3) fusion events.
September 2019—Streck introduced three antibiotic resistance detection kits and its blood collection tube at the AACC Annual Scientific Meeting and Clinical Lab Expo, Aug. 6-–8, in Anaheim, Calif.
September 2019—Meridian Bioscience has acquired Quebec City-–based GenePOC, a provider of molecular diagnostic instruments and assays.
September 2019—Ortho Clinical Diagnostics announced that its Vitros Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator (Vitros HIV Combo test) has been granted FDA premarket approval for use on Ortho’s Vitros XT 7600 Integrated System. The Vitros HIV Combo is a fourth-generation test that detects HIV-1 and HIV-2 antibodies and the p24 antigen.
